QTTB Q32 Bio Inc.

BULLISH Impact: 8/10 Insider Cluster (2 insiders)
Horizon weeks Filed Jun 2, 2026 Processed 11d 7h ago
Insider cluster: 2 insiders, $20.0M total
Latest settled — T+1d ⚠ clustered
QTTB ▼ -3.56% at T+1d
LONG call ✗ call lost -3.56% · α vs SPY -2.84% · entry $12.64 → $12.19
Next anchor: T+5d due 5d ago
Currently $12.64 · +0.00% from $12.64 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-3.56%
call -3.56% · α -2.84%
$12.19
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a total of $20M (10.1% of market cap). These open-market purchases coincide with a PIPE offering disclosed in the May 27 8-K, indicating insider participation and strong confidence at the offering price.

Key Financial Metrics

Direction
buying
Total Value
$20.0M
Insiders
2

Actionable Insight

Insider buying at the PIPE price suggests management views the stock as undervalued. The PIPE provides balance sheet support, reducing near-term financing risk. Monitor for pipeline catalysts (phase updates) that could drive re-rating.

Key Facts

  • OrbiMed Advisors LLC and Xu Diyong each bought 1,250,000 shares at $8.00 on 2026-05-28, total $20M.
  • Total insider purchase equals ~10.1% of QTTB's $198M market cap.
  • Purchases follow a Securities Purchase Agreement (8-K filed 2026-05-27) for a PIPE offering at the same $8 price.
  • Both buyers are directors and 10% owners, amplifying the signal.

Financial Impact

Insiders invested $20M at $8/share, representing 10.1% of market cap; PIPE likely raises additional capital from other investors.

dilutioncashinsider ownership

Risk Factors

  • PIPE dilutes existing shareholders; new shares represent a significant overhang.
  • Clinical-stage biotech risk; pipeline failure could impair recovery.
  • Low historical win rate on score-6/7 reports for QTTB (calibration suggests caution).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-QTTB-1780362955879
6 reports for QTTB
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+5▲ +7.86%Apr 24, 2026
Filters
Rows
Reports for QTTB — sortable, filterable
Type Now
Jun 2, 2026
11d ago
Insider Cluster
BULLISH ★ 8/10
$12.64 $12.19▼ −3.56%▼ −2.84%$12.64 (+0.00%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$5.14 $5.47▲ +6.42%▲ +5.04%$12.64 (+145.91%)
Apr 24, 2026
7w ago
8-K
BEARISH ★ 6/10
$5.47 $5.72▼ −4.57%▼ −5.06%$12.64 (−131.08%)
Apr 24, 2026
7w ago
424B5
BEARISH ★ 6/10
$5.47 $5.72▼ −4.57%▼ −5.06%$12.64 (−131.08%)
Mar 27, 2026
11w ago
424B5
BEARISH ★ 6/10
$5.90 $6.42▼ −8.81%▼ −5.92%$12.64 (−114.24%)
Feb 25, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$4.73 $4.76▲ +0.63%▲ +1.18%$12.64 (+167.23%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (52h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access